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Abstract
X-linked adrenoleukodystrophy is an X-linked recessive disorder affecting approximately 1 in 21,000
males, and is estimated to be the cause of adrenal insufficiency in approximately 35% of patients with
idiopathic Addison’s disease. The disease is caused by defective beta-oxidation of fatty acids in
peroxisomes that leads to elevated serum concentrations of very-long-chain saturated fatty acids. The
accumulation causes a primary adrenal insufficiency and progressive neurological dysfunction. This
article presents a case of X-linked adrenoleukodystrophy in its milder form, adrenomyeloneuropathy.
Case presentation
A 45-year-old white male building contractor presents to
a family practice clinic with symptoms of dysuria and
pain on micturation. He has used cranberry tablets, with
some relief. He has had this problem on and off for
20 years. He was recently treated him with doxycycline,
which failed to help. He has no history of sexually
transmitted diseases.
The patient’s history is significant for Addison’sd i s e a s e .
He was diagnosed at age 19 when he presented to a
hospital with extreme weakness. He was placed on
maintenance doses of hydrocortisone and fludrocorti-
sone. The patient reports childhood illness that included
difficulty running and a year of quarantine due to an
unidentified infection. The patient complains of unstea-
diness while walking and is concerned he might have
adrenoleukodystrophy. He had previously requested a
serum B12 test, which was normal. He feels short of
breath at times and has lower back pain. The patient is
also concerned about symptoms of irritability and
depression.
His medication list includes hydrocortisone 20 mg daily,
fludrocortisone 0.1 mg daily, escitalopram 10 mg daily,
dehydroepiandrosterone (DHEA) 50 mg daily, ibuprofen
800 mg twice daily.
Both of the patient’s parents are living. The patient’s
mother has coronary artery disease and Type II Diabetes.
The patient is one of 10 siblings, 8 living, including one set
of triplets and one set of twins. The patient is a fraternal
twin. One of the brothers died unexpectedly two weeks
after birth, another brother died of influenza at the age of
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mental retardation. A fourth brother has pronounced
ataxia.
On physical exam the patient appears well. He is 6
04
00 and
230 pounds. Blood Pressure 119/88, Pulse, 102. Lungs are
clear. Abdomen is soft and non-tender. Hyperpigmenta-
tion is clearly observed, especially on the knees. His hair
appears dry and sparse and eyelashes are minimal. There is
diminished sensation and vibration sense in his feet. Mild
ataxia is present and the patient walks with heals off the
ground. Romberg is intact. Plantar reflex is extensor
bilaterally, (Babinski sign).
Patient was treated with Ciprofloxacin for urethritis.
Endocrinology and neurology consults were sought.
Differential diagnosis
Polyglandular Endocrine Deficiency Syndrome, tubercu-
losis, Ectopic ACTH Syndrome, adrenomyeloneuropthy,
multiple sclerosis, prostate disease, Addison’s Disease, and
Triple A Syndrome, (achalasia-addisonianism-alacrima
syndrome).
Investigative results
Other tests
Discussion
The history, physical, and symptoms of our patient
resulted in the consideration of several possibilities as is
evident by our differential diagnosis list. However,
elevated concentrations of C24, C26, as well as abnor-
mally high C24/C22 and C26/C22 ratios are indicative of
hemizygosity for X-linked adrenoleukodystrophy; settling
the diagnosis [1].
X-linked adrenoleukodystrophy (X-ALD) is an X-linked
recessive disorder affecting approximately 1 in 21,000
males. This disease is caused by defective beta-oxidation of
fatty acids in peroxisomes that leads to elevated serum
concentrations of very-long-chain saturated fatty acids
(VLCFA). The accumulation of cholesterol esters of the
fatty acids and gangliosides in the membranes of cells in
the brain, adrenal cortex, and other organs causes a
primary adrenal insufficiency and progressive neurological
dysfunction. The responsible gene, called ABCD1, is
located on the long arm of the X chromosome (Xq28),
and encodes a peroxisomal membrane protein, called
ALDP (adrenoleukodystrophy protein), that belongs to
the ABC super family of transporter proteins. Many
mutations within ABCD1 have been detected.
There is considerable phenotypic variation among indivi-
duals affected with X-ALD. Broadly, cerebral adrenoleu-
kodystrophy begins in childhood and includes behavior
disturbances with rapid progression to dementia, blind-
ness, and quadriparesis. Death typically occurs within
months to several years of onset of symptoms. Adreno-
myeloneuropthy is a milder and more slowly progressing
form of X-ALD. It begins in adolescence or adulthood with
symptoms of weakness, spasticity, and distal polyneuro-
pathy and may include emotional lability, mania, or
psychosis [2,3]. Bladder dysfunction is a common
manifestation of adrenomyeloneuropathy and can be a
presenting symptom of this disease [4,5].
Males carrying an X-ALD mutation will almost invariably
develop disease, with about 50% developing adrenoleu-
kodystrophy in early childhood and 50% developing
adrenomyeloneuropathy later in adolescence or adult-
hood. Both phenotypes occur in the same family [6].
Urinalysis
Appearance: Clear yellow
Urobilinogen: Normal
Glucose: Negative
Ketone: Negative
Bilirubin: Negative
Protein: 30
Nitrite: Negative
Leukocytes: +
Blood: Negative
pH: 5
Specific Gravity: 1.030
Urine Culture: Negative
Imaging
Chest X-ray: Normal
Brain MRI:
1. Negative brain. Variation of normal asymmetry of the right lateral
ventricle.
2. Minor intrasellar cistern but essentially normal adenohypophysis as
described.
3. Chronic pansinusitis
Insulin-Like Growth Factor-1 133 In Range (90-360 ng/ml)
Testosterone: 265 In Range (241-827 NG/DL)
PSA: 1.02 (0-4.0 ng/ml)
ACTH 135 pg/ml High (15-80 pg/ml)
Fatty Acid Profile, Peroxisomal C22-C26:
C22:0 69.2 In Range (< OR = 96.3 UMOL/L)
Pristanic Acid 0.55 In Range (< OR = 2.98 UMOL/L)
Phytanic Acid 3.73 In Range (< OR = 9.88 UMOL/L)
Pristance
Phytanic
0.15 In Range (< OR = 0.39 Ratio)
C24:0 97.2 High (< OR = 91.4 UMOL/L)
C26:0 4.06 High (< OR = 1.30 UMOL/L)
C24:0/C22:0 1.40 High (< OR = 1.39 Ratio)
C26:0/C22:0 0.058 High (< OR = 0.023 Ratio)
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develop an AMN like syndrome [2].
The common concept of adrenoleukodystrophy involves
images from the popular film Lorenzo’s Oil, which was
based on the true story of a young patient with the cerebral
form of X-ALD. Although our patient had been specifically
concerned about adrenoleukodystrophy, his efforts to be
tested were always dismissed because he did not appear
extremely ill. The adrenomyeloneuropathy phenotype is
not well known, yet, our patient easily fits into its
description. Victor, Ropper 2001 report, “We are caring
for several adult men (with X-ALD) in whom the cerebral
symptoms have been mild, allowing for high level
cognitive function, the main manifestation consisting of
personality quirks, spastic gait, urinary difficulty, testicular
insufficiency, and baldness. Two of the men related the
characteristic history of a male sibling who dies in
childhood, ostensibly of Addison disease” [7].
X-ALD is estimated to be the cause of adrenal insufficiency
in approximately 35% of patients with idiopathic Addi-
son’s disease and should be considered in the differential
diagnosis of any male with adrenal insufficiency. Neuro-
logical symptoms, such as changes in gait or peripheral
neuropathy, may appear before adrenal insufficiency [8].
Patients may also present with psychiatric disturbances
months to years before onset of other problems [3].
Conclusion
Adrenal hormone replacement therapy is critical and may
be life saving. Our patient reported a brother that died of
influenza at the age of eight. From the history, it seems
likely this brother also had X-ALD and was suffering from
adrenal insufficiency. An Addisonian crisis in a young
male can be an acute presentation of X-ALD.
Data from patients with X-ALD, treated with glycerol
trioleate and glycerol trierucate in a 4:1 ratio (Lorenzo’s
oil), showed significantly reduced levels of VLCFA’s within
four weeks. Also, Lorenzo’s oil is associated with reduced
risk of developing MRI abnormalities in asymptomatic
boys with X-ALD [2]. Bone marrow transplantation
(BMT), and umbilical cord hematopoietic stem cell
transplantation (HSCT) are the only proven effective
therapy for symptomatic cerebral forms of X-ALD [10].
Early identification of X-ALD, preferably before the onset
of symptoms, is critical to maximizing treatment. Identi-
fication of hemizygotes can be made by testing levels of
VLCFA. These levels are elevated at birth, providing the
opportunity for neonatal screening. Although elevated
levels of VLCFA are clearly indicative of hemizygosity, only
85% of heterozygous females have abnormal levels.
Therefore it is recommended that male relatives in an
affected family be tested, even if their mother has normal
VLCFA levels [1].
For our patient, testing for high levels of VLCFA within
the patient’s pedigree ensued. The patient’s mother, (an
obligate carrier,) and one sister had elevated levels of
VLCFA associated with heterozygosity. A second sister had
normal levels and her three children, all boys, also had
normal levels. A third sister had a male child and he tested
normally. Thementally retarded brother hadnormal levels
of VLCFA. There were two maternal aunts with normal
results, and no maternal uncles. The patient’s brother with
ataxia refused testing. This brother had one child, a male,
which was determined not to be at risk, due to theX-linked
inheritance.
The patient and his heterozygous sister enrolled in a
clinical trial of Lorenzo’s Oil at Kennedy Kreiger Institute.
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